A Holistic Review of Systemic Lupus Erythematosus: From Inception to Intervention
DOI:
https://doi.org/10.55544/jrasb.4.3.19Keywords:
Systemic Lupus Erythematosus (SLE), Autoimmune Disease, Lupus Nephritis, Neuropsychiatric Lupus, Antinuclear Antibodies (ANA), Genetic PredispositionAbstract
SLE is a multi-system autoimmune disorder that primarily affects women of reproductive age. The specific etiology of SLE is unknown, however it is thought to be a mix of hereditary and environmental factors. The illness is defined by the development of auto-antibodies against nuclear and cytoplasmic antigens, which causes tissue and organ damage. The clinical symptoms of SLE can range from modest skin involvement to serious organ damage. SLE is diagnosed based on both clinical and laboratory data, with categorization criteria defined by EULAR and ACR being widely utilized. SLE treatment regimens vary depending on the severity of the disease and the organs involved, but constant monitoring and control are essential.Various environmental causes, including drugs, viral infections, and sun exposure, have been linked to SLE. Nail abnormalities and nail fold video capillaroscopy anomalies have been seen in SLE patients, suggesting possible links with illness severity. The therapeutic aims for SLE have evolved from decreasing side effects and organ damage to increasing health-related quality of life.
Downloads
References
Justiz Vaillant. A.A. Goyal. A. Varacallo. M.A. (2025). Systemic Lupus Erythematosus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
Molina-Rios. S. Rojas-Martinez. R. Estévez-Ramirez. G.M. Medina. Y.F. (2023). Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination.A case report. Mod Rheumatol Case Re, 7(1), 43-46.
Didier. K. Bolko. L. Giusti. D. Toquet. S. Robbins. A. Antonicelli. F. Servettaz. A. (2018) Autoantibodies associated with connective tissue diseases: what meaning for clinicians?. Front Immunol, 9, 541.
Aringer. M. Costenbader. K. Daikh. D. et al.: (2019) European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol, 71, 1400- 12.
Stratta. P. Mesiano. P. Campo. A. et al. (2009). Life expectancy of women with lupus nephritis now approaches that of the general population. Int J Immunopathol Pharmacol, 22, 1135-41.
Morand. E.F. Mosca. M. (2017). Treat to target, remission and low disease activity in SLE. Best Pract Res Clin Rheumatol, 31, 342–50.
Franklyn. K. Lau. C.S. Navarra. S.V. et al. (2016). Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis, 75, 1615–21.
Golder. V. Kandane-Rathnayake. R. Hoi. A.Y. et al. (2017). Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther, 19, 62.
Selvaraja. M. Too. C.L. Tan. L.K. Koay. B.T. Abdullah. M. Shah. A.M. Arip. M. Amin-Nordin. S. (2022). Lupus Sci Med, 9(1).
Losada-García. A. Cortés-Ramírez. S.A. Cruz-Burgos. M. Morales-Pacheco. M. Cruz-Hernández. C.D. Gonzalez-Covarrubias. V. Perez-Plascencia. C. Cerbón. M.A. Rodríguez-Dorantes. M. (2021). Hormone related cancer and autoimmune diseases: A complex interplay to be discovered. Front Genet, 12, 673180.
Tayem. M.G. Shahin. L. Shook. J. Kesselman. M.M. (2022). A review of cardiac manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome with focus on endocarditis. Cureus, 14(1), e21698.
G.J. Pons-Estel. G.S. Alarcón. L. Scofield. L. Reinlib. G.S. Cooper. (2010). Understanding the epidemiology and progression of systemic lupus erythematosus, Semin. Arthritis Rheum, 39, 257–268.
E. Krishnan. H.B. Hubert. (2006). Ethnicity and mortality from systemic lupus erythematosus in the US. Ann. Rheum. Dis, 65, 1500–1505.
Rees. F. Doherty. M. Grainge. M.J. Lanyon. P. Zhang. W. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford), 56, 1945-61.
Weckerle. C.E. Niewold. T.B. (2011). The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol, 40, 42-9.
N. Danchenko. J. Satia. M. Anthony. (2006). Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden. Lupus, 12, 308–318.
E.D. Ferucci. J.M. Johnston. J.R. Gaddy. L. Sumner. J.O. Posever. T.L. Choromanski. C. Gordon. S.S. Lim. C.G. Helmick. (2014). Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people. Arthr. Rheumatol. 66, 2494– 2502.
S.S. Lim. A.R. Bayakly. C.G. Helmick. C. Gordon. K.A. Easley. C. Drenkard. (2014). The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia lupus registry. Arthr. Rheumatol, 66, 357–368.
E.C. Somers. W. Marder. P. Cagnoli. E.E. Lewis. P. De Guire. C. Gordon. C.G. Helmick. L. Wang. J.J. Wing. J.P. Dhar. J. Leisen. D. Shaltis. W.J. McCune. (2014). Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthr. Rheumatol, 66, 369–378.
C.G. Helmick. D.T. Felson. R.C. Lawrence. S. Gabriel. R. Hirsch. C.K. Kwoh. M.H. Liang. H.M. Kremers. M.D. Mayes. P.A. Merkel. S.R. Pillemer. J.D. Reveille. J.H. Stone. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I, Arthritis Rheum, 58, 15–25.
Tsai. H.L. Chang. J.W. Lu. J.H. Liu. C.S. (2022). Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. Korean J Intern Med, 37(4), 864-876.
Hsu. T. Nguyen. P. Petronic-Rosic. V. (2022) A case of systemic lupus erythematosus with cutaneous granulomatous vasculitis. JAAD Case Rep, 21, 93-96.
Sinha. A. Rivera. A.S. Chadha. S.A. Prasada. S. Pawlowski. A.E. Thorp. E. DeBerge. M. Ramsey-Goldman. R. Lee. Y.C. Achenbach. C.J. Lloyd-Jones. D.M. Feinstein. M.J. (2021). Comparative Risk of Incident Coronary Heart Disease Across Chronic Inflammatory Diseases. Front Cardiovasc Med, 8, 757738.
Liu. T. Neuner. R. Thompson. A. Pottackal. G. Petullo. D. Liu. J. Nikolov. N. Sahajwalla. C. Doddapaneni. S. Chen. J. (2022) Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus, 31(4), 424-432.
Pan. Q. Chen. J. Guo. L. et al. (2019) Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus. Am J Transl Res, 11, 1241-54.
Brown. J.M. Archer. A.J. Pfau. J.C. Holian. (2003) A. Silica accelerated systemic autoimmune disease in lupusprone New Zealand mixed mice. Clin Exp Immunol, 131, 415-21.
Monteiro. B.G. Pizarro. C.B. (2022) Environmental and occupational exposures in the development of systemic lupus erythematosus in adults: a narrative review. Rheumatology, 61.
Costenbader. K.H. Kim. D.J. Peerzada. J. Lockman. S. Nobles-Knight. D. Petri. M. Karlson. E.W. (2004) Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum, 50, 84957.
Achtman. J.C. Werth. V.P. (2015). Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther, 17, 182.
Yu. C. Chang. C. Zhang. J. (2013) Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun, 41, 34-45.
Berner. B.R. Tary-Lehmann. M. Yonkers. N.L. Askari. A.D. Lehmann. P.V. Anthony. D.D. (2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol, 235, 29-38.
Su. R. Li. Z. Wang. Y. et al. (2020) Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia. Clin Exp Rheumatol, 38, 864-73.
Poole. B.D. Scofield. R.H. Harley. J.B. James. J.A. (2006) Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity, 39, 63-70.
Vaglio. A. Grayson. P.C. Fenaroli. P. Gianfreda. D. Boccaletti. V. Ghiggeri. G.M. Moroni. G. (2018) Drug-induced lupus: traditional and new concepts. Autoimmun Rev, 17, 912-8.
Rubin. R.L. (2005) Drug-induced lupus. Systemic Lupus Erythematosus (Second Edition). Tsokos GC (ed): Academic Press, 535-47.
Petri. M. (2008). Sex hormones and systemic lupus erythematosus. Lupus, 17, 412-5.
Karrar. S. Cunninghame Graham. D.S. (2018). Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol, 70, 496-507.
JustizVaillant. A.A. Goyal. A. Varacallo. M. (2022) Systemic Lupus Erythematosus. StatPearls Publishing, Treasure Island.
Deng. Y. Tsao. BP. (2019). Genetics of human SLE. Dubois' Lupus Erythematosus and Related Syndromes (Ninth Edition). Wallace DJ, Hahn BH (ed): Elsevier, London, 54-68.
Laurynenka. V. Kottyan. L.C. Weirauch. M.T. Kaufman. K.M. Harley. J.B. (2021) Genetic predisposition to lupus across ancestries has >300 separable genetic contributions: what we know today. Lupus Sci Med.
Armstrong. D.L. Zidovetzki. R. Alarcón-Riquelme. M.E. et al. (2014). GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region. Genes Immun, 15, 347-54.
Mak. A. Kow. N.Y. (2014). The pathology of T cells in systemic lupus erythematosus. J Immunol Res, 419029.
Al-Mayouf. S.M. Sunker. A. Abdwani. R. et al. (2011). Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet, 43, 1186-8.
Suárez-Fueyo. A. Bradley. S.J. Tsokos. G.C. (2016). T cells in systemic lupus erythematosus. Curr Opin Immunol, 43, 32-8.
Nakayamada. S. Tanaka. Y. (2021). Clinical relevance of T follicular helper cells in systemic lupus erythematosus . Expert Rev ClinImmunol, 17, 1143-50.
Tsokos. G.C. Lo. M.S. Costa Reis. P. Sullivan. K.E. (2016). New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumato., 12, 716-30.
Giang. S. La Cava. A. (2016). Regulatory T cells in SLE: biology and use in treatment. Curr Rheumatol Rep, 18, 67.
Mellor-Pita. S. Citores. M.J. Castejon. R. Tutor-Ureta. P. Yebra-Bango. M. Andreu. J.L. Vargas. J.A. (2006). Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis, 65, 553-4.
T. Katsuyama. G.C. Tsokos. V.R. Moulton. (2018). Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front. Immunol, 9.
M.K. Crow. (2017). Etiology and Pathogenesis of Systemic Lupus Erythematosus, tenth ed., Elsevier Inc.
Jenks. S.A. Sanz. I. (2009). Altered B cell receptor signaling in human systemic lupus erythematosus. Auto immun Rev, 8, 209-13.
Möckel. T. Basta. F. Weinmann-Menke. J. Schwarting. A. (2021) B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev, 20, 102736.
Shao. W.H. Cohen. P.L. (2011). Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther, 13, 202.
Pagani. S. Bellan. M. Mauro. D. et al. (2020) New insights into the role of Tyro3, Axl, and Mer receptors in rheumatoid arthritis. Dis Markers, 2020, 1614627.
Jung. J.Y. Suh. C.H. (2015). Incomplete clearance of apoptotic cells in systemic lupus erythematosus: pathogenic role and potential biomarker. Int J Rheum Dis, 18, 294-303.
Cook. H.T. Botto. M. (2006). Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol, 2, 330-7.
Leffler. J. Bengtsson. A.A. Blom. A.M. (2014). The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis, 73, 1601-6.
Deng. Y. Tsao. B.P. (2010). Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol, 6, 683-92.
Jorge. A.M. Means. T.K. (2019). Abnormalities in immune complex clearance and apoptotic cell clearance. Dubois' Lupus Erythematosus and Related Syndromes (Ninth Edition). Wallace DJ, Hahn BH (ed): Elsevier, London, 216-23.
Fillatreau. S. Manfroi. B. Dörner. T. (2021). Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol, 17, 98-108.
Chyuan. I.T. Tzeng. H.T. Chen. J.Y. (2019). Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells.
Nacionales. D.C. Kelly-Scumpia. K.M. Lee. P.Y. et al. (2007). Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum, 56, 3770-83.
Merola. J.F. Bermas. B. Lu. B. Karlson. E.W. Massarotti. E. Schur. P.H. Costenbader. K.H. (2014). Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus, 23, 77884.
McCarty. D.J. Manzi. S. Medsger. T.A. Jr. Ramsey-Goldman. R. LaPorte. R.E. Kwoh. C.K. (1995). Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum, 38, 1260-70.
Gatto. M. Saccon. F. Zen. M. Iaccarino. L. Doria. A. (2019). Preclinical and early systemic lupus erythematosus. Best Pract Res Clin Rheumatol, 33, 101422.
Schwartz. N. Stock. A.D. Putterman. C. (2019). Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol, 15, 137-52.
BAI. R. LIU. S. ZHAO. Y. et al. (2016). Depressive and anxiety disorders in systemic lupus erythematosus patients without major neuropsychiatric manifestations. J Immunol Res, 2016: 2829018.
TJENSVOLLA. A.B. LAUVSNESB. M.B. HIROHATAC. S. et al. (2016). Migraine in patients with systemic lupus erythematosus is associated with reduced cerebral grey matter volume but not with measures of glial activation or anti-NR2 or anti-P antibodies. Eur J Neurol, 23, 780-6.
SHIMIZU. Y. YASUDA. S. KAKO. Y. et al. (2016). Poststeroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev, 15, 786-94.
SHIMIZU. Y. YASUDA. S. KAKO. Y. et al. (2016). Poststeroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev, 15, 786-94.
HANLY. G.J. O’KEEFFE. A.J. SU. L. et al. (2016). The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford), 55, 252-62.
BRODER. A. MOWREY. W.B. KIM. M. et al. (2016). Association between antiphospholipid antibodies and allcause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study. Rheumatology (Oxford), 55, 817-25.
PAGNI. F. GALIMBERTI. S. GALBIATI. E. et al. (2016). Tubulointerstitial lesions in lupus nephritis: International multicentre study in a large cohort of patients with repeat biopsy. Nephrology (Carlton), 21, 35-45.
Fawzy. M. Edrees. A. Okasha. H. El Ashmaui. A. Ragab. G. (2016). Gastrointestinal manifestations in systemic lupus erythematosus. Lupus, 25, 1456-62.
ZHANG. L. XU. D. YANG. H. et al. (2016). Clinical features, morbidity, and risk factors of intestinal pseudoobstruction in systemic lupus erythematosus: a retrospective case-control. Study J Rheumatol, 43, 559-64
Medlin. J.L. Hansen. K.E. McCoy. S.S. Bartels. C.M. (2018). Pulmonary manifestations in late versus early systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum, 48, 198-204.
PÉREZ-PEÑATE. G.M. RÚA-FIGUEROA. I. JULIÁ-SERDÁ. G. et al. (2016). Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol, 43, 323-9.
WANG. H. GUO. X. LAI. J. et al. (2016). Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. Clin Exp Rheumatol, 34, 291-95.
HIGUERA. V. AMEZCUA-GUERRA. L.M. MONTOYA. H. et al. (2016). Association of nail dystrophy with accrued damage and capillaroscopic abnormalities in systemic lupus erythematosus. J Clin Rheumatol, 22, 13-8.
JUNG. J.H. SOH. M.S. AHN. Y.H. et al. (2016). Thrombocytopenia in systemic lupus erythematosus clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore), 95, e2818.
Keeling. D.M. Isenberg. D.A. (1993). Haematological manifestations of systemic lupus erythematosus. Blood Rev, 7, 199-207.
Bashal. F. (2013). Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J, 7, 87-95.
SKARE. T.L. DAGOSTINI JS. ZANARDI. P.I. et al. (2016). Infections and systemic lupus erythematosus. Einstein (Sao Paulo), 14, 47-51.
ZHENG. H. LI. M. WANG. D. et al. (2016). Genderspecific contributing risk factors and outcome of female cryptococcal meningoencephalitis patients. BMC Infect Dis, 16, 22.
PIGA. M. CASULA. L. PERRA. D. et al. (2016) Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus, 25, 28-37.
YU. K.H. KUO. C.F. HUANG. L.H. et al. (2016). Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore), 95, e3540.
KIM. T.H. BAE. S.C. LEE. S.H. et al. (2016). Association of complement receptor 2 gene polymorphisms with susceptibility to osteonecrosis of the femoral head in systemic lupus erythematosus. Biomed Res Int, 2016, 9208035.
SHOR. D.B. DAHAN. S. COMANESHTER. D. et al. (2016). Does inflammatory bowel disease coexist with systemic lupus erythematosus? Autoimmun Rev, 15, 1034-37.
KAKUTA. K. DOHI. K. SATO. Y. et al. (2016). Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr, 29, 173-80.
VIVERO. F. GONZALEZ-ECHAVARRI. C. RUIZ. B. et al. (2016). Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimm Rev, 15, 1134-40.
GUY. A. TIOSANO. S. COMANESHTER. D. et al. (2016). Aortic aneurysm association with SLE – a case-control study. Lupus, 25: 959-63.
SHARMA. S.K. RATHI. M. SAHOO. S. et al. (2016). Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis. Lupus, 25, 525- 31.
SABIO. J.M. VARGAS-HITOS. J.A. MARTINEZBORDONADO. J. et al. (2016). Cumulated organ damage is associated with arterial stiffness in women with systemic lupus erythematosus irrespective of renal function. Clin Exp Rheumatol, 34, 53-7.
HINOJOSA-AZAOLA. A. ROMERO-DIAZ. J. VARGAS-RUIZ. A.G. et al. (2016). Venous and arterial thrombotic events in systemic lupus erythematosus venous and arterial thrombotic events in systemic lupus erythematosus. J Rheumatol, 43, 576-86.
MOYA. F.B. PINEDA GALINDO. L.F. GARCIA DE LA PENA. M. (2016). Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus. J Clin Rheumatol, 22, 8-12.
Pract Res Clin Rheumatol, 23, 495-506.
Mahmoud. K. Zayat. A. Vital. E.M. (2017). Musculoskeletal manifestations of systemic lupus erythmatosus. Curr Opin Rheumatol, 29, 486-92.
Mukkera. S. Mannem. M. Chamarti. K. Pillarisetty. L. Vulasala. S.S. Alahari. L. Ammu. A. Mukkera. A. Vadlapatla. R.K. (2022). Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report. Cureus, 14(2), e22639.
Cavalli. S. Lonati. P.A. Gerosa. M. Caporali. R. Cimaz. R. Chighizola. C.B. (2022). Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. Front Pharmacol, 13, 841785.
Emorinken. A. Dic-Ijiewere. M.O. Erameh. C.O. Ugheoke. A.J. Agbadaola. O.R. Agbebaku. F.O. (2021). Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic. Reumatologia, 59(6), 402-410.
Aringer. M. Costenbader. K. Johnson. S.R. (2022). Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Rev Clin Immunol, 18(2), 135-144.
Liu. C.C. Kao. A.H. Manzi. S. Ahearn. J.M. (2013). Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis, 5, 210-33.
Aragón. C.C. Tafúr. R.A. Suárez-Avellaneda. A. Martínez. M.T. Salas. A.L. Tobón. G.J. (2020). Urinary biomarkers in lupus nephritis. J Transl Autoimmun, 3, 100042.
Pisetsky. D.S. Bossuyt. X. Meroni. P.L. (2019). ANA as an entry criterion for the classification of SLE. Autoimmun Rev, 18, 102400.
Meroni. P.L. Bizzaro. N. Cavazzana. I. Borghi. M.O. Tincani. A. (2014). Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med, 12, 38.
Su. Y. Jia. R.L. Han. L. Li. (2007). Z.G. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol, 122, 115-20.
Lim. K.L. Jones. A.C. Brown. N.S. Powell. R.J. (1993). Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann Rheum Dis, 52, 429-35.
Weinstein. A. Alexander. R.V. Zack. D.J. (2021) A review of complement activation in SLE. Curr Rheumatol Rep, 23, 16.
Fu. S.M. Dai. C. Zhao. Z. Gaskin. F. (2015). Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Res, 4, 939.
Flechsig. A. Rose. T. Barkhudarova. F. et al. (2017). What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol, 35, 598- 606.
Alba. P. Bento. L. Cuadrado. M.J. et al. (2003). Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis, 62, 556-60.
Li. C. Mu. R. Lu. X.Y. He. J. Jia. R.L. Li. Z.G. (2014). Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia. J Immunol Res, 2014, 672126.
Provost. T.T. Reichlin. M. (1981). Antinuclear antibody-negative systemic lupus erythematosus. I. Anti-Ro(SSA) and anti-La(SSB) antibodies. J Am Acad Dermatol, 4, 84-9.
Franceschini. F. Cavazzana. I. (2005). Anti-Ro/SSA and La/SSB antibodies. Autoimmunity, 38, 55-63.
Skudalski. L. Shahriari. N. Torre. K. Santiago. S. Bibb. L. Kodomudi. V. Grant-Kels. J.M. Lu. J. (2022). Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome. J Am Acad Dermatol, 87(1), 1-18.
Dima. A. Jurcut. C. Chasset. F. Felten. R. Arnaud. L. (2022). Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis, 14, 1759720X211073001.
Wafa. A. Hicham. H. Naoufal. R. Hajar. K. Rachid. R. Souad. B. Mouna. M. Zoubida. M.T. Mohamed. A. (2022). Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol, 41(7), 2021-2033.
Scheen. M. Adedjouma. A. Esteve. E. Buob. D. Abisror. N. Planche. V. Fain. O. Boffa. J.J. De Seigneux. S. Mekinian. A. Haidar. F. (2022). Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev, 21(5), 103072.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jakka Rohith Reddy, R. Anvesh, G. Anurudh Reddy, P. Veeresh Babu, N. Sree Lakshmi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
10.55544/jrasb
editor@jrasb.com or mailtojrasb@gmail.com | 
+91-8874396939
This work is licensed under a 